GlassScriptPhysician profile
Joel Goldberg
NPI 1376589655
$5,040.72
in general payments reported to CMS, 2019-2025
34 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $877 · 2021: $1,179 · 2022: $904 · 2023: $557 · 2024: $47.65 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $557.01 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $440.06 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $381.50 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $373.27 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $350.01 | 2019-2023 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $344.16 | 2019-2022 | |
| Abbott Laboratories | $343.32 | 2019-2024 | Merlin@Home, Jot Dx |
| Sanofi-Aventis U.S. LLC | $290.16 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $246.85 | 2019-2024 | Xarelto |
| Pfizer INC. | $212.17 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.61 | 2019-2022 | |
| Medtronic, INC. | $205.65 | 2021-2025 | Symplicity G3 |
| Regeneron Healthcare Solutions, INC. | $170.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $153.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $93.14 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $90.21 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $67.66 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $48.84 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $46.74 | 2019-2020 | |
| Esperion Therapeutics, INC. | $45.68 | 2020 | |
| Baxter Healthcare | $44.60 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $42.44 | 2019-2020 | |
| Eisai INC. | $40.45 | 2020-2021 | |
| Chiesi USA, INC. | $32.59 | 2021-2022 | |
| Lilly USA, LLC | $29.16 | 2022 | |
| Impulse Dynamics (USA) INC. | $28.36 | 2023 | Optimizer |
| Abbvie INC. | $27.52 | 2022 | |
| Althera Pharmaceuticals LLC | $24.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.23 | 2020 | |
| Boston Scientific Corporation | $18.32 | 2021 | |
| Edwards Lifesciences Corporation | $18.19 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $16.73 | 2019 | |
| Lundbeck LLC | $14.01 | 2020 | |
| Promius Pharma LLC | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.